Baptist Heart & Vascular Institute Research

June 2024

The BHVI research goal is to enhance patient care by offering access to the newest treatment alternatives.

The research department is conducting a study to evaluate if an investigational drug (Factor XIa) is non-inferior to apixaban for the composite of stroke and non-CNS embolism in patients with atrial fibrillation. In early studies, no major bleeding events or cardiovascular changes were noted.

If you would like additional information about our research program, please call 448.227.6690.

---

Our research goal is to enhance patient care by offering access to the newest treatment alternatives.

See our past research